TrialBMC cancer2020

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial.

Stefano Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.